Getting GHRH Dosing Right: A Step-by-Step Walkthrough

GHRH at a glance:

• Drug class: Growth hormone secretagogue
• Route: subcutaneous injection (peptides) or oral (small molecules)
• Typical frequency: once daily to once weekly depending on agent
• Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

Dosing GHRH correctly isn't complicated, but the details matter. The standard schedule is once daily to once weekly depending on agent via subcutaneous injection (peptides) or oral (small molecules), and the key decisions happen during titration.

Standard Dosing Schedule for GHRH

FDA-approved agents have specific labeled dosing. Research-only GHS peptides have no validated human dosing.

The typical schedule for GHRH is once daily to once weekly depending on agent via subcutaneous injection (peptides) or oral (small molecules). Half-life of varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677) explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For this class of compound, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms .

A typical titration plan for GHRH holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of GHRH is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in GHRH side effects and the cost angle of dose escalation in GHRH cost.

What the Trials Used

Published trial data for GHRH comes primarily from: Stanley 2010 (tesamorelin in HIV-lipodystrophy); Nass 2008 (MK-677 in older adults).

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For GHRH: the standard contraindications for this drug class apply.

Bottom Line

The single biggest dosing mistake we see with GHRH is impatience — skipping titration steps to get to the goal dose faster. It almost always backfires.

Frequently Asked Questions

Related Reading

• The Honest Guide to GHRH: What Patients and Doctors Actually Say
• Is GHRH Safe? An Honest Look at the Side-Effect Profile
• GHRH Results: What the Real Numbers Show in 2026
• GHRH Cost Explained: Monthly, Yearly, and How to Save
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.

This page is informational only and is not medical advice. We do not provide guidance for self-administration of compounds that are not FDA-approved.